Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.42 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.42 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.42 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.42 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851268 | 1.00 | ALDH1A1 (0.45) | ALDH1A1LMNASIRT6ACVR1BTGFBR1 | |
| Hydrochloric Acid SCHEMBL29379635 | 0.99 | ALDH1A1 (0.44) | ALDH1A1LMNASIRT6ACVR1BTGFBR1 | |
| Hydrochloric Acid SCHEMBL382604 | 0.99 | ALDH1A1 (0.44) | ALDH1A1LMNASIRT6ACVR1BTGFBR1 | |
| SCHEMBL26087309 | 0.88 | ALDH1A1 (0.51) | ALDH1A1LMNASIRT6MAPTTDP1 | |
| SCHEMBL224959 | 0.85 | ALDH1A1 (0.46) | ALDH1A1LMNASIRT6MAPTTDP1 | |
| SCHEMBL25725927 | 0.84 | ALDH1A1 (0.43) | ALDH1A1LMNAROCK1ROCK2PRKACA | |
| SCHEMBL375364 | 0.83 | SIRT6 (0.57) | ALDH1A1LMNASIRT6TGFBR1ACVR1 | |
| SCHEMBL29446151 | 0.83 | SIRT6 (0.57) | ALDH1A1LMNASIRT6TGFBR1ACVR1 | |
| Hydrochloric Acid SCHEMBL9014064 | 0.83 | MAPT (0.45) | ALDH1A1LMNAROCK1ROCK2PRKACA | |
| Hydrochloric Acid SCHEMBL16513834 | 0.80 | ATM (0.44) | ALDH1A1LMNAROCK1ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4074697-B1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | SAMJIN PHARM CO LTD (KR) | 2025-05-21 | — | — | EP | disclosed |
| CN-114929675-B | Adamantane derivatives as focal adhesion kinase inhibitors | 三进制药株式会社 | 2024-02-13 | — | — | CN | disclosed |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | INCHEON NATIONAL UNIVERSITY RESEARCH & BUSINESS FOUNDATION (KR) | 2023-02-16 | — | — | US | disclosed |
| EP-4074697-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | Samjin Pharmaceutical Co., Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
| CN-114929675-A | Novel adamantane derivatives as inhibitors of focal adhesion kinase | 三进制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021111311-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | 삼진제약주식회사 | 2021-06-10 | — | — | WO | disclosed |
| WO-2021018118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | WO | disclosed |
| WO-2017097113-A1 | AMINOPYRIMIDINE COMPOUNDS FOR INHIBITING ACITIVITY OF PROTEIN TYROSINE KINASE | 深圳市塔吉瑞生物医药有限公司 | 2017-06-15 | — | — | WO | disclosed |
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | ALDH1A1 864/4885LMNA 3826/4885SIRT6 1314/4885 |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | PTK2, DAPK2, DAPK1 | ALDH1A1 2271/4885LMNA 2883/4885SIRT6 3546/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | ALDH1A1 779/4885LMNA 3783/4885SIRT6 3364/4885 |
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | PTK2, CTTN, ADGRF1 | ALDH1A1 1097/4885LMNA 1512/4885SIRT6 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.